Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

The study included Screening Period (Day ‐28 to Day ‐1), double‐masked treatment period (Day 1 to Week 72), and post‐treatment follow‐up period (Week 72 to Week 76). Treatment visits were scheduled in 4‐week intervals. After 6 initial monthly injections of brolucizumab or aflibercept (loading phase), subjects entered a one‐year individualized flexible treatment (IFT) phase. During the IFT phase, an assessment of disease stability was performed at each monthly visit and subjects received either an active or a sham injection. Treatment with active was interrupted when disease stability was reached.